罗欣药业(002793) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was CNY 1,649,232,432.98, a decrease of 1.80% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2021 was CNY 139,071,646.6, an increase of 8.36% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 129,192,280.0, reflecting a year-on-year increase of 6.68%[3] - Total operating revenue for the third quarter reached ¥5,092,644,764.83, an increase of 16.8% compared to ¥4,359,067,776.89 in the same period last year[21] - Operating profit for the period was ¥525,296,818.25, up 22.4% from ¥429,340,109.01 in the previous year[22] - Net profit attributable to the parent company was ¥436,319,877.15, representing a 27.2% increase from ¥343,075,287.23 year-over-year[22] - Basic earnings per share for Q3 2021 was CNY 0.10, an increase of 11.11% year-on-year[3] - Basic earnings per share for the period were ¥0.30, compared to ¥0.24 in the same quarter last year, indicating a growth of 25%[23] - The total comprehensive income for the period was ¥448,611,358.25, up from ¥354,630,508.05, reflecting a growth of 26.5%[23] Assets and Liabilities - The total assets as of September 30, 2021, were CNY 9,304,737,005.75, representing a 20.45% increase from the end of the previous year[4] - As of September 30, 2021, total assets reached RMB 9,304,737,005.75, an increase from RMB 7,724,883,182.53 at the end of 2020, representing a growth of approximately 20.5%[17] - Current assets totaled RMB 6,246,057,984.42, up from RMB 4,883,336,909.21 at the end of 2020, indicating a growth of about 27.8%[17] - Total liabilities increased to ¥4,524,398,274.92, compared to ¥3,372,102,277.30 in the previous year, reflecting a growth of 33.9%[22] - The total liabilities stood at 3,200,000,000 CNY, with a focus on managing short-term borrowings effectively[30] - Total liabilities amounted to approximately CNY 3.37 billion, with current liabilities at CNY 2.97 billion[31] - The total current liabilities amounted to RMB 3,619,005,489.93, up from RMB 2,967,475,913.23, representing a growth of about 21.9%[18] Cash Flow - The cash flow from operating activities showed a net outflow of CNY 306,847,400.0, a 24.62% improvement compared to the same period last year[3] - The net cash flow from operating activities was -306,847,458.57 CNY, compared to -407,075,840.09 CNY in the previous year, indicating an improvement of approximately 24.5%[26] - Total cash inflow from operating activities reached 5,428,078,527.35 CNY, up from 4,495,964,005.03 CNY, representing an increase of about 20.6% year-over-year[26] - Cash outflow from operating activities totaled 5,734,925,985.92 CNY, compared to 4,903,039,845.12 CNY, reflecting a rise of approximately 17%[26] - Cash generated from operating activities was ¥4,983,921,244.97, compared to ¥4,053,680,281.78 in the previous year, showing a significant increase[25] Borrowings and Financial Expenses - Short-term borrowings rose by 36.23% to CNY 1,140,779,152.74, reflecting new loans from financial institutions[9] - The company reported a significant increase in financial expenses by 78.19% to CNY 67,113,941.37 due to increased borrowing[10] - The company’s long-term borrowings increased significantly to RMB 734,265,000.50 from RMB 303,327,464.80, reflecting a growth of approximately 142.5%[18] - Long-term borrowings stood at approximately CNY 303.33 million[31] Inventory and Receivables - Accounts receivable increased by 43.91% to CNY 3,625,099,619.88 due to business expansion[9] - Accounts receivable rose to RMB 3,625,099,619.88, compared to RMB 2,519,019,684.17 at the end of 2020, marking an increase of around 43.9%[17] - The company’s inventory increased to RMB 686,920,379.08 from RMB 646,334,419.98, which is an increase of about 6.3%[17] Research and Development - Research and development expenses were ¥225,978,379.64, a decrease of 14.3% from ¥263,711,670.76 in the previous year[22] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 3.18%, a decrease of 0.06% compared to the previous year[4] - The company reported a decrease in credit impairment losses to ¥81,126,049.63 from ¥17,150,675.43 in the previous year, indicating improved asset quality[22] - The company reported an unallocated profit of approximately CNY 2.44 billion[31] - The company has a capital reserve of approximately CNY 209.92 million[31] - The total owner's equity attributable to the parent company was approximately CNY 4.04 billion[31] - The company is implementing new leasing standards starting from 2021, which has necessitated adjustments in the financial statements[28]